Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Contineum Therapeutics (CTNM) Net Income (2023 - 2025)

Contineum Therapeutics (CTNM) has 3 years of Net Income data on record, last reported at -$15.1 million in Q4 2025.

  • For Q4 2025, Net Income fell 3.71% year-over-year to -$15.1 million; the TTM value through Dec 2025 reached -$59.8 million, down 41.54%, while the annual FY2025 figure was -$59.8 million, 41.54% down from the prior year.
  • Net Income reached -$15.1 million in Q4 2025 per CTNM's latest filing, down from -$13.0 million in the prior quarter.
  • Across five years, Net Income topped out at $41.6 million in Q2 2023 and bottomed at -$15.9 million in Q2 2025.
  • Average Net Income over 3 years is -$6.6 million, with a median of -$9.6 million recorded in 2024.
  • Peak YoY movement for Net Income: tumbled 121.66% in 2024, then fell 3.71% in 2025.
  • A 3-year view of Net Income shows it stood at -$7.8 million in 2023, then plummeted by 87.04% to -$14.6 million in 2024, then fell by 3.71% to -$15.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Net Income were -$15.1 million in Q4 2025, -$13.0 million in Q3 2025, and -$15.9 million in Q2 2025.